Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06150612
Other study ID # 20216986
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 3, 2024
Est. completion date January 1, 2025

Study information

Verified date November 2023
Source Yeshiva University
Contact Annie Kate Reeder, MA
Phone 646-592-4368
Email AReeder@mail.yu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot study that aims to understand the feasibility and acceptability of a mobile health educational app plus group-based mindfulness therapy on anxiety and migraine-related disability among people with migraine.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 24
Est. completion date January 1, 2025
Est. primary completion date July 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 or older - Meets diagnostic criteria for migraine - Reports anxiety symptoms of 5 or more on GAD-7 - Has a smartphone Exclusion Criteria: - Under the age of 18 - Presence of suicidal ideation - Reports severe depression on PHQ-9 - Lack of group readiness

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Unwinding Anxiety
In the Unwinding Anxiety arm, participants will receive 6 weeks of an educational app and weekly facilitated mindfulness groups.

Locations

Country Name City State
United States Rousso Building Bronx New York

Sponsors (1)

Lead Sponsor Collaborator
Yeshiva University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Anxiety Patient Reported Measurement Outcome System - Anxiety Short Form Score [min = 37; Max = 83; higher scores indicate higher levels of anxiety symptoms] Change from Week 0 to Week 10
Other Change in Headache-Related Disability Headache Disability Inventory Score [min = 0; max = 100; higher scores indicate higher levels of headache-related disability] Change from Week 0 to Week 10
Primary Feasibility Average number of facilitated mindfulness group sessions attended out of 6 weekly sessions 6 weeks
Secondary Acceptability Average Credibility Score from the Credibility/Expectancy Questionnaire [min = 3; max = 27; higher scores indicate higher credibility] Assessed at 6 weeks, immediately post-intervention
See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A